Abstract:The persistent transformation of quiescent hepatic stellate cells (HSCs) into myofibroblasts (MFs) and the excessive proliferation of MF-HSCs in the liver contribute to the pathogenesis of liver fibrosis, cirrhosis, and liver cancer. Glycolysis inhibition of MF-HSCs can reverse their MF phenotype and suppress their abnormal expansion. Here, we have developed vitamin A-derivative (VA) decorated PEG-PCL polymeric micelles to encapsulate the labile and hydrophobic camptothecin (CPT) and direct its active attack on HSCs, selectively inhibiting of HIF-1α and cellular glycolysis, ultimately repressing hepatic fibrogenesis. The obtained micelles exhibited a good stability, biocompatibility, pH sensitivity, and exceptional HSC-targetability, allowing an efficient accumulation of their carried CPT in acutely and chronically injured livers. On their intracellular release of CPT specifically in MF-HSCs, these CPT micelles nicely inhibited the HIF-1α and a series of glycolytic players in MF-HSCs and prominently suppressed their proliferation and MF phenotypic characteristics. Accordingly, on in vitro administration to the mice challenged by CCl4 or subjected to bile duct ligation, these VA-decorated CPT micelles ameliorated the pathological symptoms of the livers, as evidenced by the significant reduction in serum levels of ALT and AST, infiltration of inflammatory cells, and collagen accumulation, the drastic down-regulation of multiple fibrotic genes, and the good recovery of attenuated hepatocyte CYP2E1 and lipogenesis regulator PPARγ. Overall, the CPT carried by VA-decorated PEG-PCL polymeric micelles can selectively inhibit the glycolysis and expansion of HSCs and thus suppress fibrogenesis, providing an original and effective approach for anti-fibrotic therapy. STATEMENT OF SIGNIFICANCE: Our work introduces an innovative antifibrotic drug system that is developed upon the active targeting of CPT and aims for the fate reversal of HSCs. Through HSC-targeted delivery achieved by PEG-PCL polymeric micelles decorated with vitamin A-derivatives, CPT significantly suppressed the expressions of HIF-1α and glycolytic enzymes in MF-HSCs, as well as their pathologic expansion in mouse livers. It effectively ameliorated chronic liver fibrosis in mice induced by CCl4 injection or BDL and restored the damaged liver structure and function. These compelling findings demonstrate the therapeutic potential of glycolytic HSC-targeting in combating fibrosis and related disorders and thus provide new promise for future clinical management of such prevalent and life-threatening conditions.

The combined induction of liver progenitor cells and the suppression of stellate cells by small molecules reverts chronic hepatic dysfunction

Efficient Generation of Functional Hepatocyte-Like Cells from Mouse Liver Progenitor Cells Via Indirect Co-Culture with Immortalized Human Hepatic Stellate Cells.

Chemically induced revitalization of damaged hepatocytes for regenerative liver repair

Small Molecule Drugs Promote Repopulation of Transplanted Hepatocytes by Stimulating Cell Dedifferentiation

A two-step strategy to expand primary human hepatocytes in vitro with efficient metabolic and regenerative capacities

Ex-vivo expanded CD34+ cell transplantation alleviates fibrotic liver injury via innate immune modulation in metabolic dysfunction-associated steatohepatitis mice

Early Activated Hepatic Stellate Cell-Derived Paracrine Molecules Modulate Acute Liver Injury and Regeneration

Direct Reprogramming of Hepatic Myofibroblasts into Hepatocytes In Vivo Attenuates Liver Fibrosis

Human liver progenitor-like cells-derived extracellular vesicles promote liver regeneration during acute liver failure

Direct Reprogramming of Human Fibroblasts to Functional and Expandable Hepatocytes.

Hybrid Bioactive Hydrogel Promotes Liver Regeneration Through the Activation of Kupffer Cells and ECM Remodeling after Partial Hepatectomy

A Deactivation Factor of Fibrogenic Hepatic Stellate Cells Induces Regression of Liver Fibrosis in Mice

Reprogramming Fibroblasts into Bipotential Hepatic Stem Cells by Defined Factors

An Integrin-Based Nanoparticle That Targets Activated Hepatic Stellate Cells and Alleviates Liver Fibrosis.

Direct Chemical Induction of Hepatocyte‐like Cells with Capacity for Liver Repopulation

Hepatic Progenitor Cells Contribute To The Progression Of 2-Acetylaminofluorene/Carbon Tetrachloride-Induced Cirrhosis Via The Non-Canonical Wnt Pathway

Single‐Cell Transcriptomic Analysis Reveals a Hepatic Stellate Cell–Activation Roadmap and Myofibroblast Origin During Liver Fibrosis in Mice

Selective inhibition of glycolysis in hepatic stellate cells and suppression of liver fibrogenesis with vitamin A-derivative decorated camptothecin micelles

Establishment of Functional Liver Spheroids From Human Hepatocyte-Derived Liver Progenitor-Like Cells for Cell Therapy

Agonist c-Met Monoclonal Antibody Augments the Proliferation of hiPSC-derived Hepatocyte-Like Cells and Improves Cell Transplantation Therapy for Liver Failure in Mice

Synergetic Regulation of Kupffer Cells, Extracellular Matrix and Hepatic Stellate Cells with Versatile CXCR4-inhibiting Nanocomplex for Magnified Therapy in Liver Fibrosis